U-CRI • Center for Research in Immunology

News

7th Research Day on Tumor Immunology and Immunotherapy program

Don't miss Aurélie, Panagiotis, Solange and Abdullah who have been selected for oral presentation!

Stil time to register (open until October 1)

08h30 – 09h30 Registration and Coffee
09h30 – 09h40 Welcome and Introduction
Prof. Dr. An Coosemans, KU Leuven – Belgium
09h40 – 10h25 Macrophage Subsets In Tumor Immunity
Prof. Julie Helft, INSERM - Paris - France
10h25 – 11h10 Selected Abstracts: Jolien Van Craenenbroeck, Karo Van Lil, Aurélie Detavernier
Chair: Prof. Evelien Smits, U Antwerp – Belgium
11h10 – 11h20 LiveDrop-Bio: The ModaFlow™, a microfluidic instrument for high-throughput singlecell
analysis and 3D immune cells studies by Dr. Natacha Coppieters
Chair: Prof. Stanislas Goriely, ULB – Belgium
11h20 – 11h30 InVivo BioTech Services: Facilitating Immunotherapy From Concept to Pre-clinic: 25
years experience & cutting-edge technology by Mr. Haijie Li
Chair: Prof. Stanislas Goriely, ULB – Belgium
11h30 – 13h00 Lunch and Poster Viewing
13h00 – 13h45 Exploiting TCR Promiscuity to Drive Scalability in Neoantigen Targeting
Prof Christopher Klebanoff, MSKCC – New York - USA
13h45 – 14h30 Selected Abstracts: Pauline Bardet, Panagiotis Vistos, Solange Dejolier
Chair: Prof. Sophie Lucas, UCL - Belgium
14h30 – 15h15 Coffee Break
15h15 – 16h00 Selected Abstracts: Sebastian Igelmann, Daniel Flender, Abdullah Mayet
Chair: Prof. Sophie Janssens, U Ghent – Belgium
16h00 – 16h45 Molecular Imaging of Immunotherapy & the Immune System
Prof. Elisabeth de Vries, UMCG – The Netherlands
16h45 – 17h00 Closing Remarks and Poster/Presentation Awards
Chair: Prof. Jo Van Ginderachter & Prof. Geert Raes VUB - Belgium

Latest news

ANNUAL BIS MEETING

September 23rd 2025 - 16:59

Date: Tuesday November 18th 2025

Venue: Palais des Congrès de Liège, Esplanade de l'Europe, 4020 Liège/Luik/LuHch

08:30 – Welcome and RegistraNon

Plenary Session 1: Mucosal Immunology and InfecNon (09:30–10:45)
- 09:30–10:05 | Keynote: Yasmine Belkaid (Title TBD) (30 min + 5 Q&A)
- 10:05–10:20 | Invited Belgian speaker (TBD, 12 + 3 Q&A)
- 10:20–10:45 | Talk selected from the abstracts (12 + 3 Q&A)

10:45–11:15 – Coffee Break

Plenary Session 2: Neuroimmunology and InflammaNon (11:15–12:30)
- 11:15–11:45 | Yvonne Dombrowski (Title TBD) (25 + 5 Q&A)
- 11:45–12:00 | Invited Belgian...

Uncovering Cellular Factors Driving Success or Failure of Immunotherapy

September 16th 2025 - 15:49

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet many patients fail to respond. To investigate why, Jelena Gabrilo and colleagues from the lab of immunobiology used a preclinical model in which only part of the mice respond to anti-PD-1 therapy, enabling direct comparison between responding and non-responding settings.
This study, published in Cancer Immunology Research showed that tumors responding to treatment were enriched in tumor-reactive CD8⁺ T-cell clones expressing high levels of Tim-3, suggesting these cells are key drivers of the anti-tumor response. They...

When inflammation protects the gut

April 02nd 2025 - 09:41

Tristetraprolin (TTP) is an RNA-binding protein that plays a major role in the control of inflammation. TTP KO mice spontaneously develop a complex multi-organ inflammatory syndrome but no overt intestinal inflammation, suggesting the involvement of local regulatory mechanisms. In this study published in the European J of Immunology and led by Bérengère de Toeuf and Maxime Melchior in the team of Stanislas Goriely, the researchers observed local expansion of IL-22-producing type 3 innate lymphoid cells (ILC3s) in the lamina propria of TTP KO mice. They show that these mice were...

New publication in Gut microbes on the dynamic connection between the maternal microbiome and the offspring immunity

January 06th 2025 - 15:27

Influenza virus causes a significant threat to neonatal health characterized by a less robust anti-viral adaptive CD8 T-cell response. In this publication, researchers from the group of Véronique Flamand (IMI) uncovered how maternal probiotic supplementation during pregnancy and lactation empowers neonatal immunity. By enhancing the development and protective function of effector and memory CD8 T cells, probiotics offer robust defense against influenza virus in offspring. Furthermore, in collaboration with the team of Amandine Everard (UCLouvain), they showed profound changes in the...

Solange Dejolier présentera ses travaux de thèse en cours lors de la première édition d'automne d'Immuno-Connect, organisée à l'Institut GIGA de l'Université de Liège le 24 octobre, de 16h à 21h.

September 23rd 2024 - 15:10

Solange Dejolier (du laboratoire d'Immunobiologie) présentera ses données récentes sur les rôles des voies de signalisation PD-1 et CD27 dans la différenciation des lymphocytes T résidents mémoires et T épuisés dans le foie.

The public defence in order to obtain the PhD in Sciences degree of JELENA GABRILO

September 23rd 2024 - 14:52

The role of the tumor microenvironment in shaping the response to anti-PD-1 therapy

JELENA GABRILO
will be held on
WEDNESDAY, OCTOBER 2ND, AT 3:00 PM AT:
The Brachet Seminar Room, Gosselies Campus
12, Rue des Professeurs Jeneer et Brachet, 6041 Gosselies

as well as online via Teams: QR code (click on the title above)

YBIS 1st annual Meeting (Young Immunological Society)

August 29th 2024 - 13:36

Senior Scientists are welcome.

https://youngbis.be/information/

New publication in Science Translational Medicine on the imprinting of monocytes by vaccine adjuvants

August 14th 2024 - 14:27

Most vaccines based on recombinant antigens rely on coadministration with an adjuvant to elicit a robust immune response. Although adjuvants are needed for many vaccines, it is less clear which adjuvant(s) should be paired with each immunogen. In this article, GSK and IMI researchers from the group of Fabienne Willems and Arnaud Marchant showed that an AS01-adjuvanted hepatitis B virus vaccine, which induces robust CD4+ T cell responses against the vaccine antigen, also elicited trained immunity in human recipients, which was not observed in an Alum-adjuvanted vaccine. These data demonstrate...

Guillem Sanchez Sanchez is selected as a finalist for the F.R.S.-FNRS best PhD thesis prize in Biomedical and Pharmaceutical Sciences

July 09th 2024 - 18:07

Guillem Sanchez Sanchez, from David Vermijlen's laboratory, defended his thesis in December 2023, entitled “Decoding early life γδ T cell ontogeny and their response to bacterial infection through the lens of single-cell transcriptomics”. Recently, Guillem was selected as one of three finalists for the F.R.S.-FNRS in Biomedical and Pharmaceutical Sciences. He will present his work together with the two other finalists at the end of October 2024 on the UCLouvain campus in Brussels.